Lilly Articles
Lilly and MacroGenics sign teplizumab accord
29 October 2007
Iroko buys Canadian antibiotic rights
22 October 2007
Review of the annual meeting of the ECNP
22 October 2007
FDA warns on Byetta's pancreatitis risk
22 October 2007
GE and Lilly to collaborate on cancer drug analysis
22 October 2007
Eli Lilly CEO Taurel calls for reform of US drug safety system
15 October 2007
Lilly adds warnings to Zyprexa and Symbyax
15 October 2007
Headlines 25 years ago this week....
8 October 2007
UPDATE: China's fake Rx drug factories exposed, imitation Viagra "would give overdose"
1 October 2007
Lymphoma drug gets EU Orphan Status
1 October 2007
Patent expiries will reduce bipolar drug market $400M
1 October 2007
Lilly files Alimta with EMEA for NSCLC
1 October 2007
Lilly Japan moves into GP market with Cialis
1 October 2007
Robert Heine joins Lilly as executive medical director for Diabetes and Endocrine unit
27 September 2007
Lilly's Evista cleared by FDA for reducing risk of breast cancer
24 September 2007
Eli Lilly's HumaPen Luxura available in the UK
24 September 2007
Lilly sponsors China-Europe diabetes R&D program
24 September 2007
Janssen and AstraZeneca drugs now lead antipsychotics
24 September 2007
Spot checks for fake drugs demonstrated
17 September 2007
World Conference on Lung Cancer highlights important developments
17 September 2007
Japan stock market week to September 3, 2007
10 September 2007
Headlines 25 years ago this week....
3 September 2007
Cymbalta cuts fibromyalgia pain severity
3 September 2007
Lilly's Alimta appeal turned down by NICE committee
3 September 2007
Headlines 25 years ago this week....
20 August 2007
Competition in the venous thromboembolism market
20 August 2007
Dosing initiated in Ph III balaglitazone trial
6 August 2007
ODAC OKs Evista for breast cancer prevention
30 July 2007
Lilly's 2nd-qtr 20% sales hike beats estimates
30 July 2007
NICE changes course on mesothelioma drug
26 July 2007
SMC OKs Lilly's Byetta as insulin alternative
23 July 2007
Teva sales forecast to reach $13.3B by 2010
16 July 2007
EC approves Lilly's Cialis
2 July 2007
SSRIs lower BMD in men and women
2 July 2007
Eli Lilly partners US groups on TB drug R&D
25 June 2007
Dale Edgar joins Eli Lilly
18 June 2007
Barr drops challenge on Lilly's US Zyprexa patent
18 June 2007
Lilly to appeal generic Zyprexa rulings
18 June 2007
Lilly reports benefits of Alimta in NSCLC
11 June 2007
Mylan gets final OK from FDA for fluoxetine 40mg
11 June 2007
Less pain for depressives switched to duloxetine
4 June 2007
Strong Ph III data for Organon's asenapine
4 June 2007
Cymbalta improves SDS score in GAD patients
4 June 2007
Fake parallel trade drug hits UK, product recall
4 June 2007
Foreign investors overcome China scandal fears
28 May 2007
Alex Azar has joins Eli Lilly
14 May 2007
New Hampshire data mining law overturned
14 May 2007
US health care reform group launches
14 May 2007
Lilly launches diabetes drug Byetta in the UK
14 May 2007
Australian R&D tax breaks announced
14 May 2007
Headlines 25 years ago this week....
30 April 2007
Lilly's Strattera added to Australian PBS
30 April 2007
Lilly's MDR-TB strategy lauded by IFPMA
23 April 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
Amylin's 1st-qtr 2007 net loss narrows 27.2%
23 April 2007
Grassley seeks Zyprexa safety and selling data
16 April 2007
UK
16 April 2007
Daiichi Sankyo completes post-merger integration
9 April 2007
Eli Lilly Japan's 2006 sales up 7% to $700M
2 April 2007
Lilly to invest further $50M to fight MDR-TB
2 April 2007
Boehringer Ingelheim's duloxetine addresses emotional symptoms and pain in depression trial
26 March 2007
Polish biotech Bioton buys Biopartners
26 March 2007
Lilly's MITP may treat alcohol addiction
19 March 2007
Lilly to buy Hypnion for access to drugs
12 March 2007
Waxman investigates marketing practices
12 March 2007
AstraZeneca begins Ph III Zactima trial
5 March 2007
Headlines 25 years ago this week....
5 March 2007
US FDA approves Lilly's Cymbalta in GAD
5 March 2007
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
